HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Published online before print November 20, 2007

This Article Full Text Full Text (PDF) All Versions of this Article: jlb.0707498v1 83/2/280    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, G. Articles by Li, Y. Search for Related Content PubMed PubMed Citation Articles by Chen, G. Articles by Li, Y.

(Journal of Leukocyte Biology. 2008;83:280-287.)
© 2008 by Society for Leukocyte Biology

Essential roles of TGF-β in anti-CD3 antibody therapy: reversal of diabetes in nonobese diabetic mice independent of Foxp3⁺CD4⁺ regulatory T cells

Guojiang Chen^*,1, Gencheng Han^*,1, Jianan Wang^*, Renxi Wang^*, Ruonan Xu^*, Beifen Shen^*, Jiahua Qian and Yan Li^*,2

^* Department of Molecular Immunology, Institute of Basic Medical Sciences, Beijing, China; and
Vaccine Branch, National Cancer Institute, Bethesda, Maryland, USA

² Correspondence: Department of Molecular Immunology, Institute of Basic Medical Sciences, Taiping Road, No. 27, Beijing, 100850, China. E-mail: liyan62033{at}yahoo.com.cn

ABSTRACT

Anti-CD3 mAb have potentials to treat overt autoimmunity as reported recently. However, the underlying mechanisms remain unclear. In this report, using an animal model of type 1 diabetes, we found that TGF-β1, an important immunoregulatory cytokine, plays a critical role in anti-CD3-mediated diabetes reversion and immune tolerance. Anti-CD3 treatment increased the TGF-β1 production, lasting for a long period of time, which contributed to maintaining peripheral tolerance by controlling pathogenic cells. Furthermore, we found that anti-CD3 treatment did not increase the forkhead box p3+ (Foxp3⁺)CD4⁺ regulatory T cells (Tregs). When fractionated from anti-CD3-treated, remitting mice and cotransferred with splenic cells from diabetic NOD mice, these Tregs failed to inhibit diabetes development in NOD.scid mice. Moreover, we found that the depletion of these Tregs did not affect an anti-CD3-mediated, therapeutic effect and the level of TGF-β1 production, which suggested that an increased level of TGF-β1 may not derive from these Tregs. Thus, our data showed a dispensable role of Foxp3⁺CD4⁺ Tregs in anti-CD3 antibody-reversed diabetes in NOD mice. These findings may have an important implication for understanding the involved mechanisms responsible for immunomodulatory function of anti-CD3 antibody on autoimmune diseases.

Key Words: autoimmunity • immunotherapy • cytokine • regulatory lymphocyte

This article has been cited by other articles:

				P. P. Sarangi, B. Kim, and B. T. Rouse Non-mitogenic Anti-CD3F(ab')2 Monoclonal Antibody: A Novel Approach to Control Herpetic Stromal Keratitis Invest. Ophthalmol. Vis. Sci., December 1, 2008; 49(12): 5425 - 5433. [Abstract] [Full Text] [PDF]

				G. Chen, G. Han, J. Wang, R. Wang, R. Xu, B. Shen, J. Qian, and Y. Li Induction of Active Tolerance and Involvement of CD1d-Restricted Natural Killer T Cells in Anti-CD3 F(ab')2 Treatment-Reversed New-Onset Diabetes in Nonobese Diabetic Mice Am. J. Pathol., April 1, 2008; 172(4): 972 - 979. [Abstract] [Full Text] [PDF]